Brava Diagnostics raises $4 million to bring acute care tests to clinical trial
BOULDER — Brava Diagnostics Inc., a Boulder biotech company, has raised $4 million in capital.
The company is raising the funds through an equity offering, according to a Form D filed with the U.S. Securities and Exchange Commission on Nov. 15.
Byron Hewett, CEO of Brava, said the company specializes in acute care diagnostics, such for the diagnosis and management of heart attacks. Brava is developing its diagnostic tests using a platform developed by MBio Diagnostics — another Boulder-based company.
Hewett said the $4 million the company has raised is going toward finishing…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!